To rule out the probability of dose dumping from an oral CR dosage form, USP has included which sampling time point for in vitro dissolution test where D is normal dosing interval
To address the question about sampling time points included by the United States Pharmacopeia (USP) for in vitro dissolution tests to rule out the probability of dose dumping from an oral controlled release (CR) dosage form, we need to understand the concept of dose dumping and the purpose of in vitro dissolution testing.
Understanding Dose Dumping: Dose dumping refers to the rapid release of a drug from a controlled release dosage form, leading to a spike in drug concentration. This can cause toxicity and negate the advantages of sustained drug delivery.
In Vitro Dissolution Testing: This is an essential step in formulation development and quality control. It helps ensure consistent drug release profiles and can predict the in vivo performance of a dosage form.
The USP has suggested specific time points for dissolution testing to monitor the release pattern of the drug. For controlled release formulations, it's crucial to ensure that the drug is released gradually over the specified dosing interval. Sampling at different fractions of the dosing interval helps in assessing the performance of the CR formulation.
Among the given options, 0.25D (where D is the dosing interval) is the key sampling time point included by USP. This early sampling time point is critical as it allows for the detection of any initial rapid release (or dose dumping) from the dosage form.
Justification of the Correct Option:
Hence, the correct answer is \(0.25D\). This time point is included for detecting any immediate release of the drug that could potentially lead to dose dumping.
Decrease in effective surface area available to the dissolution medium leading to a fall in the dissolution rate, may happen due to which one of the following reasons?
| List I | List II | ||
| A | When two dosage forms have equal t max | I | When their total body clearance is constant. |
| B | AUC values of the two analogs can be compared to measure relative bioavailability | II | Absorption rate constants are equal |
| C | Urinary data is valid to measure bioavailability. III. W | III | When fraction absorbed and elimination rate is constant. |
| D | C max is proportional to the rate of absorption | IV | Excretion of drug and/or metabolite is related to the bioavailable dose. |
Choose the correct answer from the options given below: